CY1111140T1 - 1,5-διφαινυλ-3-βενζυλαμινο-1,5-διυδροπυρρολιδιν-2-ονη ως διαμορφωτες του υποδοχεα cb1 - Google Patents

1,5-διφαινυλ-3-βενζυλαμινο-1,5-διυδροπυρρολιδιν-2-ονη ως διαμορφωτες του υποδοχεα cb1

Info

Publication number
CY1111140T1
CY1111140T1 CY20111100093T CY111100093T CY1111140T1 CY 1111140 T1 CY1111140 T1 CY 1111140T1 CY 20111100093 T CY20111100093 T CY 20111100093T CY 111100093 T CY111100093 T CY 111100093T CY 1111140 T1 CY1111140 T1 CY 1111140T1
Authority
CY
Cyprus
Prior art keywords
diffinyl
dihydropyrrolidine
benzylamino
receptor modulators
schizophrenia
Prior art date
Application number
CY20111100093T
Other languages
Greek (el)
English (en)
Inventor
David Scott Coffey
Jingdan Hu
Stacy Jo Keding
Joseph Herman Junior Krushinski
John Mehnert Schaus
David Edward Tupper
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1111140T1 publication Critical patent/CY1111140T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20111100093T 2006-10-23 2011-01-27 1,5-διφαινυλ-3-βενζυλαμινο-1,5-διυδροπυρρολιδιν-2-ονη ως διαμορφωτες του υποδοχεα cb1 CY1111140T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
EP07871197A EP2094684B1 (en) 2006-10-23 2007-10-22 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidin 2-ones as cb1 receptor modulators

Publications (1)

Publication Number Publication Date
CY1111140T1 true CY1111140T1 (el) 2015-06-11

Family

ID=39386481

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100093T CY1111140T1 (el) 2006-10-23 2011-01-27 1,5-διφαινυλ-3-βενζυλαμινο-1,5-διυδροπυρρολιδιν-2-ονη ως διαμορφωτες του υποδοχεα cb1

Country Status (23)

Country Link
US (2) US7998985B2 (OSRAM)
EP (2) EP2099784B1 (OSRAM)
JP (2) JP5331002B2 (OSRAM)
KR (2) KR101088229B1 (OSRAM)
CN (2) CN101528733B (OSRAM)
AR (1) AR063497A1 (OSRAM)
AT (1) ATE492543T1 (OSRAM)
AU (1) AU2007329808B2 (OSRAM)
BR (1) BRPI0717347A2 (OSRAM)
CA (2) CA2667372C (OSRAM)
CL (1) CL2007003002A1 (OSRAM)
CY (1) CY1111140T1 (OSRAM)
DE (1) DE602007011495D1 (OSRAM)
DK (2) DK2099784T3 (OSRAM)
EA (2) EA015175B1 (OSRAM)
ES (2) ES2356025T3 (OSRAM)
MX (2) MX2009004054A (OSRAM)
PE (1) PE20080926A1 (OSRAM)
PL (2) PL2099784T3 (OSRAM)
PT (2) PT2099784E (OSRAM)
SI (2) SI2099784T1 (OSRAM)
TW (1) TW200825067A (OSRAM)
WO (2) WO2008070306A2 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1
EA201071222A1 (ru) * 2008-04-22 2011-12-30 Эли Лилли Энд Компани Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1
PL2280961T3 (pl) 2008-04-22 2012-12-31 Lilly Co Eli Związki 1,5-difenylo-pirolidyn-2-onu jako ligandy CB-1
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
DE112011102349T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2022132803A1 (en) * 2020-12-14 2022-06-23 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
KR20060131908A (ko) * 2004-02-19 2006-12-20 솔베이 파마슈티칼스 비. 브이 Ｃｂ1-길항 활성을 갖는 이미다졸린 유도체
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1

Also Published As

Publication number Publication date
ES2356025T3 (es) 2011-04-04
EP2094684A2 (en) 2009-09-02
ATE492543T1 (de) 2011-01-15
JP2010507590A (ja) 2010-03-11
DK2094684T3 (da) 2011-03-14
EP2094684B1 (en) 2010-12-22
PL2099784T3 (pl) 2013-05-31
DK2099784T3 (da) 2013-01-14
WO2008070305A2 (en) 2008-06-12
TW200825067A (en) 2008-06-16
KR101088229B1 (ko) 2011-11-30
US7998985B2 (en) 2011-08-16
KR101088236B1 (ko) 2011-11-30
JP5331001B2 (ja) 2013-10-30
CA2667372A1 (en) 2008-06-12
PL2094684T3 (pl) 2011-05-31
PT2099784E (pt) 2013-01-04
SI2099784T1 (sl) 2013-02-28
AR063497A1 (es) 2009-01-28
CN101528733A (zh) 2009-09-09
PE20080926A1 (es) 2008-07-19
WO2008070305A3 (en) 2008-08-28
MX2009004054A (es) 2009-04-27
KR20090069316A (ko) 2009-06-30
PT2094684E (pt) 2011-01-28
US20100016375A1 (en) 2010-01-21
KR20090071613A (ko) 2009-07-01
EP2099784B1 (en) 2012-12-12
CN101528733B (zh) 2013-10-16
CA2667372C (en) 2013-09-03
WO2008070306A2 (en) 2008-06-12
JP2010507589A (ja) 2010-03-11
CL2007003002A1 (es) 2008-06-06
AU2007329807A1 (en) 2008-06-12
EP2099784A2 (en) 2009-09-16
CA2667210A1 (en) 2008-06-12
EA200970404A1 (ru) 2009-10-30
WO2008070306A3 (en) 2008-07-31
AU2007329808A1 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
DE602007011495D1 (de) 2011-02-03
US8168659B2 (en) 2012-05-01
MX2009004053A (es) 2009-04-27
EA015175B1 (ru) 2011-06-30
EA015745B1 (ru) 2011-10-31
BRPI0717347A2 (pt) 2014-01-14
US20090275618A1 (en) 2009-11-05
JP5331002B2 (ja) 2013-10-30
CA2667210C (en) 2013-09-24
AU2007329808B2 (en) 2013-11-07
SI2094684T1 (sl) 2011-04-29
ES2398388T3 (es) 2013-03-15
EA200970405A1 (ru) 2009-12-30
CN101528732B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
CY1111140T1 (el) 1,5-διφαινυλ-3-βενζυλαμινο-1,5-διυδροπυρρολιδιν-2-ονη ως διαμορφωτες του υποδοχεα cb1
CY1115188T1 (el) Πολυκυκλικες ετεροαρυλ-υποκατεστημενες τριαζολες χρησιμες ως αναστολεις του axl
CY1109610T1 (el) Παραγωγο βενζιμιδαζολης και η χρηση αυτου ως ανταγωνιστου του υποδοχεα αιι
CY1120045T1 (el) Διαμορφωτες μεταφορεων κασετας δεσμευσης με ατρ
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
CY1119175T1 (el) Καινοτομες τρικυκλικες ενωσεις
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1113757T1 (el) Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων
CY1112151T1 (el) Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1113734T1 (el) Χημικες ενωσεις
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CY1113767T1 (el) Παραγωγα πυριδινης χρησιμα ως ενεργοποιητες γλυκοκινασης
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MX2010001170A (es) Derivados de imidazolona, metodo de preparacion de los mismos y uso biologico de los mismos.
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1112919T1 (el) Παραγωγα β-αμινοξεων για τη θεραπευτικη αντιμετωπιση του διαβητη
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica